MCID: SCL017
MIFTS: 40

Sclerosing Hemangioma

Categories: Cancer diseases

Aliases & Classifications for Sclerosing Hemangioma

MalaCards integrated aliases for Sclerosing Hemangioma:

Name: Sclerosing Hemangioma 12 15 73
Cutaneous Fibrous Histiocytoma 73
Sclerosing Haemangioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:495
SNOMED-CT 68 134302009 72079004
UMLS 73 C1509148

Summaries for Sclerosing Hemangioma

MalaCards based summary : Sclerosing Hemangioma, also known as cutaneous fibrous histiocytoma, is related to hemangioma of lung and cavernous hemangioma. An important gene associated with Sclerosing Hemangioma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Arf6 trafficking events and Cell adhesion_Cadherin-mediated cell adhesion. The drugs Doxorubicin and Mechlorethamine have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and bone.

Wikipedia : 76 Benign fibrous histiocytomas (also known as dermal dendrocytoma,dermatofibroma,fibrous... more...

Related Diseases for Sclerosing Hemangioma

Diseases related to Sclerosing Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 286)
# Related Disease Score Top Affiliating Genes
1 hemangioma of lung 31.1 NKX2-1 SFTPB
2 cavernous hemangioma 30.0 MUC1 SYP
3 pulmonary sclerosing hemangioma 29.8 CHGA CTNNB1 CTNND1 KRT7 NKX2-1 SFTPB
4 carcinoid syndrome 29.5 CHGA ENO2 SYP
5 papillary adenocarcinoma 29.3 KRT7 MUC1 NKX2-1
6 neuroendocrine tumor 27.5 CHGA ENO2 KRT7 NKX2-1 SYP
7 lung cancer 26.4 CHGA CTNNB1 ENO2 KRT7 NKX2-1 SYP
8 fibrous histiocytoma 11.4
9 cutaneous fibrous histiocytoma 11.1
10 hemangioma 10.8
11 chordoid glioma 10.8 MUC1 NKX2-1
12 sarcomatoid mesothelioma 10.8 MUC1 NKX2-1
13 clear cell meningioma 10.8 CHGA MUC1
14 ovarian small cell carcinoma 10.7 MUC1 SYP
15 embryoma 10.7 NKX2-1 SYP
16 esophageal neuroendocrine tumor 10.7 CHGA SYP
17 perivascular epithelioid cell tumor 10.7 MUC1 SYP
18 anaplastic ependymoma 10.7 MUC1 SYP
19 adenoma of the pancreas 10.7 CHGA SYP
20 acinar cell cystadenocarcinoma 10.7 CHGA SYP
21 peritoneal serous adenocarcinoma 10.7 CHGA SYP
22 cellular ependymoma 10.7 CHGA SYP
23 primary hepatic neuroendocrine carcinoma 10.7 CHGA SYP
24 gastrointestinal neuroendocrine tumor 10.7 CHGA SYP
25 sertoli cell tumor 10.7 MUC1 SYP
26 conventional angiosarcoma 10.6 CHGA SYP
27 pancreatoblastoma 10.6 CHGA SYP
28 papilloma of choroid plexus 10.6 MUC1 SYP
29 ureter, cancer of 10.6 CHGA SYP
30 newborn respiratory distress syndrome 10.6 NKX2-1 SFTPB
31 tanycytic ependymoma 10.6 CHGA SYP
32 non-functioning pancreatic endocrine tumor 10.6 CHGA SYP
33 pleomorphic xanthoastrocytoma 10.6 CHGA SYP
34 rhabdoid cancer 10.6 MUC1 SYP
35 pancreatic cystadenocarcinoma 10.5 CHGA SYP
36 binswanger's disease 10.5 CHGA SYP
37 tubular adenocarcinoma 10.5 CHGA MUC1
38 lobular neoplasia 10.5 CTNNB1 MUC1
39 pilomatrix carcinoma 10.5 ENO2 MUC1
40 intracranial cysts 10.5 ENO2 MUC1
41 microcystic adenoma 10.5 ENO2 MUC1
42 ossifying fibromyxoid tumor 10.5 ENO2 MUC1
43 intracranial primitive neuroectodermal tumor 10.4 CHGA ENO2
44 rete testis adenocarcinoma 10.4 ENO2 NKX2-1
45 breast papillary carcinoma 10.4 CHGA SYP
46 central nervous system organ benign neoplasm 10.4 CTNNB1 SYP
47 polymorphous low-grade adenocarcinoma 10.4 CTNNB1 MUC1
48 acute thyroiditis 10.4 CHGA ENO2
49 malignant sertoli cell tumor 10.4 ENO2 SYP
50 pancreatic somatostatinoma 10.4 ENO2 SYP

Graphical network of the top 20 diseases related to Sclerosing Hemangioma:



Diseases related to Sclerosing Hemangioma

Symptoms & Phenotypes for Sclerosing Hemangioma

Drugs & Therapeutics for Sclerosing Hemangioma

Drugs for Sclerosing Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
2
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
3
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
4
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
5
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
12
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
13
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
14 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
20 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
21 Etoposide phosphate Phase 3,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1
24 Antimitotic Agents Phase 3,Phase 2,Phase 1
25 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
26
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
27
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
28
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
29
Indinavir Approved Phase 2 150378-17-9 5362440
30
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
33
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
34
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177
35
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
36
Bevacizumab Approved, Investigational Phase 2 216974-75-3
37
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 5284616 6436030 46835353
38
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
39
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
40
nivolumab Approved Phase 2,Phase 1 946414-94-4
41
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
42
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
43
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
44
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
45
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
47
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
48 Exatecan Investigational Phase 2 171335-80-1
49
Camptothecin Experimental Phase 2 7689-03-4
50
Saracatinib Investigational Phase 2 379231-04-6

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
8 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
11 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
14 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
15 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
16 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
17 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
18 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
19 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
20 Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes Completed NCT00887809 Phase 2 gemcitabine;docetaxel;bevacizumab
21 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
22 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung Completed NCT00503295 Phase 2
23 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
24 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
25 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
26 Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma Completed NCT00085475 Phase 2 imatinib mesylate
27 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
28 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
29 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
30 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
31 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
33 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
34 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
35 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
36 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
37 Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma Recruiting NCT03123276 Phase 1, Phase 2 Pembrolizumab;Gemcitabine
38 Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma Recruiting NCT03307616 Phase 2 Nivolumab;Ipilimumab
39 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
40 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery Recruiting NCT02500797 Phase 2
41 Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Recruiting NCT03190174 Phase 1, Phase 2 Nab-Rapamycin
42 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
43 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
44 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
45 A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma Active, not recruiting NCT00667342 Phase 2 Cisplatin;Doxorubicin;Methotrexate;Ifosfamide;etoposide
46 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Active, not recruiting NCT01962103 Phase 1, Phase 2 nab-paclitaxel
47 Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Suspended NCT02923778 Phase 2
48 Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
49 Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Stage IB, Stage II, or Stage III Soft Tissue Sarcoma Terminated NCT00740597 Phase 2
50 Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery Completed NCT00450736 Phase 1 celecoxib

Search NIH Clinical Center for Sclerosing Hemangioma

Genetic Tests for Sclerosing Hemangioma

Anatomical Context for Sclerosing Hemangioma

MalaCards organs/tissues related to Sclerosing Hemangioma:

41
Lung, Skin, Bone, Liver, Endothelial, Lymph Node, Thyroid

Publications for Sclerosing Hemangioma

Articles related to Sclerosing Hemangioma:

(show top 50) (show all 172)
# Title Authors Year
1
<sup>18</sup>F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma. ( 29930720 )
2018
2
Utility of contrast-enhanced ultrasonography with perflubutane in evaluating indications for diagnostic percutaneous tumor biopsy in a case of hepatic sclerosed hemangioma. ( 29931440 )
2018
3
Pneumocytoma (sclerosing hemangioma), a potential pitfall. ( 28398699 )
2017
4
Pulmonary sclerosing hemangioma with a rare symptom: A case report and review of the literature. ( 28357098 )
2017
5
Sclerosing hemangioma of the lung showing strong FDG avidity on PET scan: Case report and review of the current literature. ( 27222778 )
2016
6
Preoperative Diagnosis in 46 Cases of Pulmonary Sclerosing Hemangioma. ( 27231179 )
2016
7
Co-occurrence of bronchial papilloma and pulmonary sclerosing hemangioma in a male. ( 27812454 )
2016
8
Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. ( 27601661 )
2016
9
Clinical case report: Sclerosing hemangioma of the liver, a rare but great mimicker. ( 27257450 )
2016
10
Pulmonary Hilar Tumor: An Unusual Presentation of Sclerosing Hemangioma. ( 27761142 )
2016
11
Sclerosing hemangioma: A diagnostic dilemma in fine needle aspiration cytology. ( 27168758 )
2016
12
Ectopic ACTH syndrome caused by pulmonary carcinoid tumor mimicking long-standing sclerosing hemangioma. ( 26828249 )
2016
13
Bone metastasis in pulmonary sclerosing hemangioma. ( 26552471 )
2015
14
Multiple hepatic sclerosing hemangioma mimicking metastatic liver tumor successfully treated by laparoscopic surgery: Report of a case. ( 25679307 )
2015
15
Incidental finding of a sclerosing hemangioma in a Caucasian woman. ( 26193226 )
2015
16
Sclerosing hemangioma of the lung. ( 26223076 )
2015
17
Sclerosing Hemangioma of the Lung Mimicking Pulmonary Metastasis. ( 25762452 )
2015
18
The significance of p40 expression in sclerosing hemangioma of lung. ( 25130377 )
2014
19
Pulmonary sclerosing hemangioma with lymph node metastasis: A case report and literature review. ( 24944657 )
2014
20
Pulmonary sclerosing hemangioma: a unique epithelial neoplasm of the lung (report of 26 cases). ( 23587094 )
2013
21
Diagnosis of sclerosing hemangioma of lung: don't rely on fine-needle aspiration cytology diagnosis alone. ( 24518736 )
2013
22
Unusual coexistence of pulmonary sclerosing hemangioma and pericardial cyst. ( 24887810 )
2013
23
Cytologic features of sclerosing hemangioma of the lung on crush preparations. ( 21710650 )
2013
24
A rare tumor of the lung: pulmonary sclerosing hemangioma (pneumocytoma). ( 23290153 )
2013
25
Histogenesis of pulmonary sclerosing hemangioma and significance of P63 expression. ( 23910931 )
2013
26
18F-FDG PET/CT features of pulmonary sclerosing hemangioma. ( 22291338 )
2013
27
A sclerosing hemangioma of the liver. ( 24459649 )
2013
28
Synchronous occurrence of breast cancer and pulmonary sclerosing hemangioma: management and review of the literature. ( 23838116 )
2013
29
A hepatic sclerosed hemangioma with significant morphological change over a period of 10 years: a case report. ( 23714181 )
2013
30
Pneumocytoma (formerly known as sclerosing hemangioma of the lung): a rare cause of chest pain. ( 23380035 )
2013
31
Napsin A is differentially expressed in sclerosing hemangiomas of the lung. ( 23194051 )
2012
32
Pulmonary sclerosing hemangioma presenting with dense spindle stroma cells: a potential diagnostic pitfall. ( 23227905 )
2012
33
A case of pulmonary sclerosing hemangioma with low (18)FDG uptake in PET. ( 22740968 )
2012
34
Treatment of 28 patients with sclerosing hemangioma (SH) of the lung. ( 22515818 )
2012
35
In pulmonary sclerosing hemangioma expression of I^-catenin, Axin, and C-myc differs between the two cell types. ( 22614067 )
2012
36
Fine-needle aspiration diagnosis of sclerosing hemangioma (pneumocytoma): Report of a case and review of the literature. ( 22645055 )
2012
37
Sclerosing hemangioma of the lung manifesting as a cystic lesion with an air-fluid level. ( 22832056 )
2012
38
Pulmonary sclerosing hemangioma: report of two cases. ( 22943472 )
2012
39
Pulmonary sclerosing hemangioma with pleural dissemination: report of a case. ( 21264765 )
2011
40
A case of sclerosing hemangioma forming a pedunculated mass. ( 21881332 )
2011
41
Sclerosing hemangioma in the liver. ( 22102394 )
2011
42
Determination of clonal status of pulmonary sclerosing hemangioma with X-chromosome inactivation mosaicism and polymorphism of phosphoglycerate kinase and androgen receptor genes. ( 20422318 )
2011
43
Coexistence of pulmonary sclerosing hemangioma and primary adenocarcinoma in the same nodule of lung. ( 21599956 )
2011
44
Pulmonary sclerosing hemangioma: pitfalls in management. ( 21471259 )
2011
45
Comparison of genetic and epigenetic alterations at 11 tumor suppressor loci in pulmonary sclerosing hemangioma and adenocarcinoma. ( 21649526 )
2011
46
A case of pulmonary sclerosing hemangioma surrounded by giant cystic change on high-resolution computed tomography. ( 20634757 )
2011
47
F-18 FDG PET/CT in evaluation of pulmonary sclerosing hemangioma. ( 21467848 )
2011
48
Microscopic sclerosing hemangioma diagnosed by histopathological examination after lung cancer surgery. ( 21881377 )
2011
49
Surgery for Pulmonary Sclerosing Hemangioma: Lobectomy versus Limited Resection. ( 22263122 )
2011
50
Pulmonary sclerosing hemangioma in a 21-year-old male with metastatic hereditary non-polyposis colorectal cancer: report of a case. ( 21645337 )
2011

Variations for Sclerosing Hemangioma

Expression for Sclerosing Hemangioma

Search GEO for disease gene expression data for Sclerosing Hemangioma.

Pathways for Sclerosing Hemangioma

GO Terms for Sclerosing Hemangioma

Biological processes related to Sclerosing Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 adherens junction organization GO:0034332 9.16 CTNNB1 CTNND1
2 epithelial tube branching involved in lung morphogenesis GO:0060441 8.96 CTNNB1 NKX2-1
3 entry of bacterium into host cell GO:0035635 8.62 CTNNB1 CTNND1

Sources for Sclerosing Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....